Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and Pathological Responses in Borderline Resectable or Unresectable Stage III NSCLC By Ogkologos - June 3, 2025 68 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a multicentre cohort study Source RELATED ARTICLESMORE FROM AUTHOR Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer EMA Recommends Extension of Indications for Cabozantinib MOST POPULAR Bladder Cancer Trial Finds Extended Lymph Node Surgery Doesn’t Improve Survival November 6, 2024 NALIRIFOX Improves Survival Compared with Nab-paclitaxel Plus Gemcitabine in First-Line Treatment... September 22, 2023 Should People with Cancer and Cancer Survivors Get the Flu Vaccine? September 2, 2020 Trial Should Change Care for AIDS-Related Kaposi Sarcoma in Sub-Saharan Africa March 10, 2020 Load more HOT NEWS As Use of Genomic Data Expands in Cancer Care, Patients Share... FDA Approves Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma ctDNA-Guided Therapy with Pertuzumab plus Trastuzumab for HER2-Amplified mCRC What Is Scanxiety? How People With Cancer and Survivors Can Cope
